|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
This study potentially offers an innovative therapeutic avenue for the NSCLC with L858R/T790M-mutated EGFR.
|
30237564 |
2018 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Together, exon 19 deletion and exon 21 L858R gene substitution are present in about 10% of Caucasian patients and 20-40% of Asian patients with non-small cell lung cancer.
|
25855240 |
2016 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Here, we report a case of an advanced chemotherapy-resistant NSCLC, harboring a novel HER3(V855A) somatic mutation homologous to the EGFR(L858R)activating mutation.
|
26689995 |
2016 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Eight patients received an EGFR TKI: three cases with G719X plus another mutation had partial responses (PRs) to erlotinib; of three cases with L858R plus another mutation, two displayed PRs and one (with EGFR-L858R+A871G) progressive disease (PD) to erlotinib; one NSCLC with EGFR-L861Q+E709A and one with delL747_T751+R776S had PRs to EGFR TKIs.
|
23242437 |
2013 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
First-generation <i>EGFR</i> TKIs, binding competitively and reversibly to the ATP-binding site of the <i>EGFR</i> tyrosine kinase domain, have resulted in a significant improvement in outcome for NSCLC patients with activating <i>EGFR</i> mutations (L858R and Del19).
|
28149837 |
2016 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells.
|
26375053 |
2015 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The trial was conducted in 17 US academic and community medical centers among 88 patients with EGFR exon 19 deletion or exon 21 L858R mutation based on local testing and stage 4 NSCLC who were eligible for bevacizumab.
|
31393548 |
2019 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The MELROSE study, a French multicentric, open label, phase II trial (ClinicalTrials.govNCT03865511) plans to enroll 150 patients with treatment-naive advanced EGFR-mutated (L858R or exon 19 deletion) NSCLC, age ≥ 18 years, with an Eastern Cooperative Oncology Group performance status 0 or 1.
|
31648999 |
2020 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer.
|
27081078 |
2016 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We used ddPCR to assess the utility of measuring plasma concentrations of common epidermal growth factor receptor (EGFR) mutations (L858R, exon 19 deletion, and T790M) in 57 non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (EGFR-TKIs).
|
28061461 |
2017 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
It may be considered that there is no difference in the clinical efficacy of gefitinib between NSCLC patients who harbor the exon 19 deletion and those with the L858R point mutation.
|
25034225 |
2014 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Increasing evidence has demonstrated that exon 19 deletions (Del19) and L858R mutation in EGFR have different prognostic and predictive roles in NSCLC.
|
28576746 |
2017 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletions or exon 21 (L858R) mutations.
|
24844234 |
2014 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer.
|
28357677 |
2017 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Circulating tumor DNA (ctDNA) is released into the circulation by tumor cell turnover and has been shown to be detectable in urine.<b>Experimental Design:</b> We tested the hypothesis that dynamic changes in EGFR activating (exon 19del and L858R) and resistance (T790M) mutation levels detected in urine could inform tumor response within days of therapy for advanced non-small cell lung cancer (NSCLC) patients receiving osimertinib, a second-line third-generation anti-EGFR tyrosine kinase inhibitor.<b>Results:</b> Eight of nine evaluable NSCLC patients had detectable T790M-mutant DNA fragments in pretreatment baseline samples.
|
28420725 |
2017 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We examined the diagnostic accuracy of the cumulative smoking dose for identifying the epidermal growth factor receptor (EGFR) exon 19 deletion and L858R mutation among Japanese patients with non-small-cell lung cancer (NSCLC).
|
19650855 |
2009 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Compound 8 exhibited good microsomes stabilities and pharmacokinetic properties and lower binding affinity to hERG ion channel than AZD9291 and displayed strong antiproliferative activity against the H1975 non-small cell lung cancer (NSCLC) cells bearing T790M/L858R and in vivo anticancer efficacy in a human NSCLC (H1975) xenograft mouse model.
|
28426996 |
2017 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Question 34: Why is epidermal growth factor receptor (EGFR) 19 Del-positive tumor more sensitive to targeted therapy than EGFR 21 L858R-positive tumor in patients with non-small cell lung cancer?
|
28571582 |
2017 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva, Astellas Pharma Inc., Northbrook, IL, http://www.us.astellas.com/) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
|
24868098 |
2014 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Collectively, compound <b>13</b>, a novel hederagenin-NO donor hybrid with a different chemical structure from those of the current FDA-approved EGFR-targeted anti-NSCLC drugs, may be a promising lead compound for the treatment of NSCLC expressing gefitinib-resistant EGFR with a T790 M mutation or osimertinib-resistant EGFR-LTC with an L858R/T790M/C797S mutation.
|
31718182 |
2019 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Targeting L858R/T790M/C797S mutant EGFR is a major challenge in the new-generation EGFR tyrosine kinase inhibitors development for conquering drug resistant NSCLC.
|
31787359 |
2020 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
|
30030903 |
2018 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In particular, a number of EGFR mutants that demonstrate ligand-independent signaling are common in non-small cell lung cancer (NSCLC), including kinase domain mutations L858R (also called L834R) and exon 19 deletions (e.g., ΔL747-P753insS), which collectively make up nearly 90% of mutations in NSCLC.
|
26337388 |
2015 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Treatment-naive patients with stage IIIB or IV NSCLC and a common EGFR mutation (exon 19 deletion or Leu858Arg) were randomly assigned (1:1) to receive afatinib (40 mg per day) or gefitinib (250 mg per day) until disease progression, or beyond if deemed beneficial by the investigator.
|
27083334 |
2016 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We retrospectively evaluated the clinical effects and safety profiles of second-line cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with NSCLC harboring sensitive EGFR mutations (exon 19 deletion/exon 21 L858R mutation).
|
29737372 |
2018 |